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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S135Results: We have monitored the efﬁciency of chondrocyte depletion
and effects on ECM recovery by quantiﬁcation of dsDNA, glyco-
saminoglycans (GAGs), and protein within the hypotonic solution.
While the majority of proteins were found in the guanidine-HCl extract
as expected, using the discovery approach and sequential extraction, we
identiﬁed several unique proteins from the extraction residue, such as
ﬁbrillin-1 and collagen IX. The extractability of proteins using guani-
dine-HCl was calculated for approximately 40 proteins using quanti-
tative proteomics and MRM.
Conclusions: We have optimized the protocol to minimize confounding
by intracellular proteins and managed to perform mass spectrometry
analysis targeting both extractable cartilage proteins and the cartilage
residue. Our results suggest that although conventional guanidine-HCl
extraction is capable of extracting proteins from cartilage, the adaptations
of this method provide ameans of analyzing the cartilage ECM that is not
confounded by intra-cellular protein and that can account for the wealth
of collagen and collagen associated proteins in the cartilage residue after
guanidine extraction. Such a method is essential for conducting com-
prehensive proteomic analysis of the cartilage in health and disease.Acknowledgement:
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AUTOPHAGY ACTIVATION PROTECTS FROM MITOCHONDRIAL
DYSFUNCTION IN HUMAN CHONDROCYTES
B. Carames y, P. Lopez de Figueroa y, M. Lotz z, F.J. Blanco y.
yOsteoarticular and Aging Res. Lab, INIBIC–Complejo Hosp.ario Univ.rio
A Coru~na, A Coru~na, Spain; zDept. of Molecular and Experimental Med.,
The Scripps Res. Inst., La Jolla, CA, USA
Purpose: A common feature of osteoarthritis (OA) and aging-related
diseases, is the progressive accumulation of damaged macromolecules
leading to cell dysfunction and death. Autophagy, a key pathway of
cellular homeostasis by removing such damaged molecules and
organelles, including mitochondria, has a protective and survival-pro-
moting function. Recent studies indicate that autophagy activity in the
articular cartilage is defective in aging and OA, contributing to the
accumulation of damaged macromolecules. In addition, there is
increasing evidence that mitochondrial dysfunction plays a critical role
in accelerating the aging process, and several lines of evidence associate
mitochondrial dysfunction to OA cartilage. The objective of this study is
to determine whether activation of autophagy protects from mito-
chondrial dysfunction in human chondrocytes.
Methods: Human chondrocyteswere treatedwith Rotenone (10 mg/ml),
Antimycin (40 mg/ml) and Oligomycin (10 mg/ml), a mitochondrial res-
piratory chain (MRC) inhibitors of complex I, III and IV, respectively.
Mitochondrial function and cell death were evaluated by Flow Cytom-
etry (FC), Fluorescence Microscopy (FM). Autophagy activation was
analyzed by determination of LC3-II, a main marker of autophagy
activation by Immunoﬂuorescence (IF) and Western Blot (WB). To
investigate whether autophagy protects from mitochondrial dysfunc-
tion, autophagy was induced by mTOR inhibition, using mTORC1
selective inhibitor Rapamycin (Rapa, 10 mM) and mTORC1 and mTORC2
inhibitor Torin 1 (50 nM). The effects on autophagy, mitochondrial
function and chondrocyte viability were analyzed by IF, WB, FC and FM.
Functional studies were performed by genetic approach using siAtg5, a
essential autophagy marker for autophagosome formation, to evaluate
the role of autophagy on mitochondrial dysfunction.
Results: Mitochondrial dysfunction was induced by 6 h treatment with
MRC inhibitors, which signiﬁcantly decreased mitochondrial membrane
potential (Djm) (ROT: 26.17  5.9; AA: 18.21  3.28; Oligo: 41.74  7.59,
expressed as % vs control; *p < 0.01). These results are consistent with
increased ROS production (26.8%, 44.6% and 25.7% for ROT, AA and Oligo,
respectively; *p< 0.001) and cell death by apoptosis at 12 h (Control: 13.56
 1.83; ROT: 33.66  5.55; AA: 29.05  4.262; *p < 0.05). Autophagy
activity determined by LC3-II was increased at short incubation times,
perhaps acting as an early response to stress and then decrease in a time
dependent manner. To evaluate whether autophagy regulates mitochon-
drial dysfunction, chondrocytes were pretreated with Rapa and Torin 1 for4 h and then treated with theMRC inhibitors for 12 h. The results show an
increase in LC3expression compared toMRC inhibitorsalone. Furthermore,
autophagy inducers Rapa and Torin1 increasedDjm (Rapa: 125.8 20.74;
RapaþROT: 44.6710.37; RapaþAA: 30.715.949; RapaOligo: 108.5
55.03 and Torin 1: 90.34  9.17; Torin 1þROT: 35.24  2.7; Torin 1þAA:
41.98  6.49; Torin 1þOligo: 98.19  16.81; *p < 0.05), decreased ROS
production (*p < 0.05) and reduced cell death, suggesting a protective
effectof autophagyactivationonpharmacologically inducedmitochondrial
dysfunction. Importanly, blocking autophagy by siAtg5 showed a sig-
niﬁcant dysfunctional changes in theDjmandROS production (*p< 0.05),
indicating the essential role of autophagy in mitocondrial function.
Conclusions: These data identify autophagy activation as a protective
mechanism from mitochondrial dysfunction in human chondrocytes.
Pharmacological interventions that enhance autophagy may have
chondroprotective activity in pathological articular cartilage with
defects on mitochondrial function.
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SMOC2 MODULATES CHONDROGENESIS BY INTERFERINGWITHWNT
AND BMP SIGNALING PATHWAYS
F. Cailotto, F.P. Luyten, R.J. Lories. KU Leuven, Leuven, Belgium
Purpose: Osteoarthritis (OA) is a highly disabling pathology of the bone-
cartilage unit, to which both patient-dependent (weight excess,
trauma/) and genetic factors contribute. A proteomic analysis of OA
cartilage revealed an increase in SPARC-relatedmodular calciumbinding
protein-2 (SMOC2). SMOC2 was originally identiﬁed by isolation from a
chondrogenic extract of articular cartilage togetherwith GDF5 and FRZB,
other proteins associated with the pathogenesis of OA. As aspects of
endochondral bone formation are seen in OA (loss of stable phenotype,
hypertrophy), we investigated the role of SMOC2 in chondrogenesis.
Methods: Three independent stable clonal colonies of the ATDC5
chondrogenic cell line, control (empty vector/GIPZ) and SMOC2 over-
expressing (SMOC2þ) or knocked-down cells (SMOC2-), were used.
Clones were cultured as high density micromasses (2 x 105 cells/10 ml).
Chondrogenesis was induced by culturing cells for 14 days (D) in DMEM/
F12þ 5% FBSþ ITS [insulin (10 mg/ml), transferrin (10 mg/ml) and sodium
selenite (30 nM)]. On D14, cells were switched to mineralization
medium (aMEMþ 5% FBSþ ITS) to investigate the mineralization phase
of chondrogenesis. mRNA expression of typical chondrogenesis markers
(Aggrecan (Agg), type II (Col2a1) and X (Col10a1)) collagens were
assessed byquantitative RT-PCR. Likely,weassessedmRNAexpression of
Wnts (-3a, -4, -5a, -5b, -11) and BMPs (-2, -4, -6, -7). Quantiﬁcation of
Alcian Blue, Safranin O, Sirius red and Alizarin red staining were used to
evaluate proteoglycans, collagens and mineralized content respectively.
Western blot was used to check the activation of BMP and Wnts path-
ways. Cell viability was checked with Live/Dead assay.
Results: In SMOC2þ cells, during the early (D1-7) and late proliferation
phase (D7-14), Col2a1 and Agg mRNA were less increased compared to
controls. Safranin O and Alcian blue stainingwere also less upregulated in
SMOC2þ. This was consistent with a lower activation of Smad 1/5/8 in
SMOC2þ. Col10a1 mRNA increased as expected from D14 onwards,
although it was signiﬁcantly lower in SMOC2þ compared to control cells.
SMOC2 overexpression also affected Wnt mRNA levels, notably by
reducing Wnt11. During mineralization phase (D14 to D21), Col10a1
mRNA was strongly increased, but to a lesser extent in SMOC2þ, and
alizarin red was much stronger in controls. The SMOC2- cells exhibited
opposite features as SMOC2þ. In the D1-D14 phases, Collagen and Pro-
teoglycan contentwashigher than in controls, alike Col2a1mRNA level. In
the D14-21 phase, these differencesweremaintained, and Col10a1mRNA
level was higher in SMOC2-, and a trend was found for a higher miner-
alizationcontent inSMOC2-.Nodifferencewasdetected incell viability for
both SMOC2þ and SMOC2- compared to their respective controls.
Conclusions: SMOC2 modulates the chondrogenesis process, by
affecting the BMP-Smad and Wnt signaling pathways.
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GSK3b INHIBITION INDUCES TERMINAL DIFFERENTIATION AND
EXTRACELLULAR MATRIX REMODELLING IN HUMAN
OSTEOARTHRITIC ARTICULAR CHONDROCYTES
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F. Flamigni x, G. Trisolino k, A. Facchini y,z, R. Borzì y. y Laboratorio di
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di Scienze Biomediche e Neuromotorie (DIBINEM), Universita di Bologna,
Bologna, Italy; kChirurgia Ricostruttiva dell’anca e del ginocchio, Istituti
Ortopedici Rizzoli, Bologna, Italy
Purpose: b catenin activation has been demonstrated to be pivotal in
chondrogenesis and a ﬁne balance of its levels is required to maintain
the healthy chondrocyte phenotype in adult articular cartilage. Never-
thless, if Wnt signalling cascade seems to be involved in osteoarthritis
(OA) development, a complete understanding of the downstream
mechanisms leading to b catenin activation and its effective role in the
disease is still missing. Among the effectors, the constitutive active
kinase GSK3b is the main regulator of intracellular b catenin levels.
GSK3b inhibition resulting in b catenin activation has been linked to OA
degeneration in rat model but emerging evidences suggest that human
cartilage might have different regulations of the Wnt pathway com-
pared to rodents. Thus, the aim of the study was to investigate the role
of GSK3b inhibition in human cartilage, to characterize its involvement
in OA development and progression, in particular to point out the
effective role in OA chondrocyte differentiation. Moreover, as GSK3b is
involved in other molecular pathways besides b catenin control, we
aimed at understanding the resulting effect of its inhibition in the
context of human chondrocytes and OA.
Methods: In order to characterize GSK3b in human OA cartilage, 9 tissue
samples of OA knee cartilage were analysed by immunoﬂuorescence (IF)
to assess levels of GSK3b inactive form (phospho-Ser9). In order to test
the effects of GSK3b inhibition on chondrocyte differentiation in vitro, 3D
cultures were established with P1 chondrocytes from 5 OA patients.
Micromasses were left to mature for one and two weeks in control
conditions (DMEM, 10%FBS, 50 mg/ml ascorbic acid), with the addition of
5mM LiCl or 10mM of SB216763 to inhibit GSK3b. Micromasses for
immunostainings were frozen in OCT. To evaluate differentiation pro-
gression, IF of nuclear localization of active b catenin and Runx2 was
performed with confocal microscopy. Mineralization was evaluated by
alizarin red staining and calcium quantitative assay on micromass sec-
tions or acidic extraction of insoluble extracts of the protein lysates,
respectively. Cell viability was evaluated by live and dead staining at the
end ofmicromassmaturation.Matrixmetalloproteinase (MMP-10,MMP-
13) expression was evaluated in lysates and starved supernatants with
western blotting and ELISA. In starved supernatants metalloprotease
activity was tested with collagen I and collagen II zymography.
Results: IF analyses of cartilage tissues for phospho-GSK3b expression
and localization revealed the presence of the inhibited form of GSK3b in
the cytoplasm of chondrocytes across the cartilage depth. In micro-
masses treated with GSK3b inhibitors we observed increased b catenin
and Runx2 nuclear translocation, with statistical signiﬁcance at 1 week,
supporting enhancement of differentiation. We also found signiﬁcantly
increased mineralization and number of dead cells after LiCl or
SB216763 mediated GSK3b inhibition, associated to a higher remodel-
ing of the micromass matrix structure. Indeed, GSK3b inhibition led to
increased expression and release in supernantants of MMP-10, known
to be a pivotal procollagenase activator in OA. Furthermore the
expression and activation of MMP-13, the main collagenase involved in
OA matrix remodelling, increased after GSK3b inhibition. Indeed,
zymography revealed a strongly increased metalloprotease activity
after GSK3b inhibition, against all tested substrates.
Conclusions: Collectively our data indicate that GSK3b inhibition in
human OA chondrocytes enhances differentation through hypertrophic
phenotype toward terminal stage. GSK3b inhibition heavily impacts on
extracellular matrix remodelling, inducing increased metalloproteases
expression and activation.Figure 1. (a) Human (H) and bovine (B) aggrecan (A1D1) fragments
detected by Western blot after incubation with or without human or
bovine synovial ﬂuid (SF) and joint capsule (JC). (b) Aggrecanase cleavage
sites in human and bovine aggrecan and fragments produced after
digestion are shown.Acknowledgement:
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217
DOES JOINT CAPSULE AND SYNOVIAL FLUID CONTAIN PROTEASES
CAPABLE OF DEGRADING AGGRECAN?
M. Hansson y, P. Sw€ard y, Y. Wang z, L.S. Lohmander y,x, A. Grodzinsky z,
A. Struglics y. y Lund Univ., Clinical Sci. Lund, Lund, Sweden; zDept. of
Biological Engineering, Massachusetts Inst. of Technology, Cambridge,MA, USA; xRes. Unit for Musculoskeletal Function and Physiotherapy,
and Dept. of Orthopaedics and Traumatology, Odense, Denmark
Purpose: Trauma induces a cascade of events in the joint, which can
result in proteolytic degradation of the cartilage and OAwhere aggrecan
is one of the ﬁrst components to be degraded. It has been proposed that
aggrecan can be further degraded by proteases in the synovial ﬂuid (SF)
environment and that the joint capsule (JC), including the synovium,
can be a source of proteases. We aimed to investigate if the JC contains
proteases which are capable of degrading aggrecan and if there are
differences in the capacity to degrade aggrecan between healthy bovine
SF and SF from joints of injured patients.
Methods: Adult human aggrecan (from arthroplasty OA knee cartilage)
and immature bovine aggrecan (from the cartilage of the patellofemoral
groove of a 1-2 week old calf) were puriﬁed by CsCl density gradient
centrifugation to collect the A1D1 fraction. Human SF was aspirated
from two patients with knee injury, and SF and JC were collected from
healthy joints of 1-2 week old calf. SF (human or bovine) was added to
aggrecan (human or bovine), and JC was added to bovine aggrecan and
incubated for 1 h or 24 h at 37oC. The aggrecan fragments were then
puriﬁed by Alcian blue precipitation, deglycosylated, separated on SDS-
PAGE and visualized by Western blot using anti-aggrecan neoepitope
antibodies ARGS, FFGV and antibodies against the aggrecan G3 domain.
Results: Incubation of human or bovine aggrecan with bovine SF
showed that large aggrecan fragments were degraded and shorter G3
(GRGT-, GLGS-, AGEG- and LGQR-G3) and ARGS (ARGS-Chondroitin
sulfate 1 and/or 2 regions (CS1/CS2)) fragments were generated (Fig. 1).
Incubation of human or bovine aggrecan with human SF showed vir-
tually the same aggrecan fragmentation pattern as was observed for the
bovine SF, although the aggrecanase activity against the interglobular
domain (IGD) site (seen as ARGS fragments) in bovine aggrecan seems
to be less than against the human aggrecan IGD site. (Fig. 1). One hour
incubation of bovine A1D1 with JC resulted in low aggrecanase activity,
although after 24h incubation all full length aggrecan monomers had
been cleaved and were detected on Western blot as newly formed
AGEG-, LGQR-, ARLE-G3 and ARGS-CS1/CS2 fragments (Fig. 1). No or
only minor increases in FFGV fragments that indicate MMP activity
were seen on Western blot after incubation of human or bovine
aggrecan with human or bovine SF or with JC (data not shown).
